These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8562855)

  • 21. [Endocrinologic aspects of benign prostatic hyperplasia (prostatic adenoma). (Can hormone therapy of the disease be justified in 1984?)].
    Holló I; Horváth C
    Orv Hetil; 1984 Oct; 125(44):2675-8. PubMed ID: 6208526
    [No Abstract]   [Full Text] [Related]  

  • 22. [The etiology of benign prostatic hyperplasia--recent findings].
    Lindner UA; Zisman A; Lindner A
    Harefuah; 1999 Jan; 136(2):161-4. PubMed ID: 10914188
    [No Abstract]   [Full Text] [Related]  

  • 23. Benign hypertrophy of the prostate.
    Mogere RM; Baraza R
    East Afr Med J; 2007 Dec; 84(12):553-5. PubMed ID: 18402305
    [No Abstract]   [Full Text] [Related]  

  • 24. Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle.
    Yokota T; Honda K; Tsuruya Y; Nomiya M; Yamaguchi O; Gotanda K; Constantinou CE
    Prostate; 2004 Feb; 58(2):156-63. PubMed ID: 14716740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prostate as an endocrine organ: androgens and estrogens.
    Ekman P
    Prostate Suppl; 2000; 10():14-8. PubMed ID: 11056488
    [No Abstract]   [Full Text] [Related]  

  • 26. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hormonal treatment of prostatic hypertrophy with special reference to the usefulness of gestagens].
    Musierowicz A
    Wiad Lek; 1974 Nov; 27(22):1985-8. PubMed ID: 4140619
    [No Abstract]   [Full Text] [Related]  

  • 28. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.
    Platz EA; Giovannucci E
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):237-53. PubMed ID: 15663987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Keratinocyte growth factor expression in hormone insensitive prostate cancer.
    Leung HY; Mehta P; Gray LB; Collins AT; Robson CN; Neal DE
    Oncogene; 1997 Aug; 15(9):1115-20. PubMed ID: 9285567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of hormones on the human fetal prostate.
    Zondek LH; Zondek T
    Contrib Gynecol Obstet; 1979; 5():145-58. PubMed ID: 365451
    [No Abstract]   [Full Text] [Related]  

  • 32. The development of androgen-independent prostate cancer.
    Feldman BJ; Feldman D
    Nat Rev Cancer; 2001 Oct; 1(1):34-45. PubMed ID: 11900250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of estrogen/androgen synergism in the pathogenesis of benign prostatic hyperplasia.
    Walsh PC
    J Urol; 1988 Apr; 139(4):826. PubMed ID: 2451038
    [No Abstract]   [Full Text] [Related]  

  • 35. [Points of view in assessment and treatment of prostatic hypertrophy].
    Aberle B
    Wien Med Wochenschr; 1971 Sep; 121(37):638-42. PubMed ID: 4106789
    [No Abstract]   [Full Text] [Related]  

  • 36. Growth factors as mediators of androgen action during male urogenital development.
    Cunha GR
    Prostate Suppl; 1996; 6():22-5. PubMed ID: 8630224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogens and benign prostatic hyperplasia: rationale for therapy with aromatase inhibitors.
    Henderson D
    Ann Med; 1991 Aug; 23(3):201-3. PubMed ID: 1718322
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia.
    Desgrandchamps F
    Eur Urol; 1997; 32 Suppl 1():28-31. PubMed ID: 9218940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacologic control of hypophyseal tumors: interactions of estrogens, thyroid hormones, growth and anti-growth factors].
    Nedvídková J; Schreiber V; Stárka L; Pacák K
    Cas Lek Cesk; 2000 Dec; 139 Suppl 1():19-21. PubMed ID: 11262896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathology of benign prostatic hyperplasia.
    Roehrborn CG
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S11-8. PubMed ID: 19002119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.